These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 25139337)
41. Measles, mumps, rubella antibody surveillance: pilot study in Grampian, Scotland. Narayan KM; Moffat MA Health Bull (Edinb); 1992 Jan; 50(1):47-53. PubMed ID: 1612895 [TBL] [Abstract][Full Text] [Related]
42. Response to measles-mumps-rubella vaccine in children on dialysis. Schulman SL; Deforest A; Kaiser BA; Polinsky MS; Baluarte HJ Pediatr Nephrol; 1992 Mar; 6(2):187-9. PubMed ID: 1571219 [TBL] [Abstract][Full Text] [Related]
43. The combination measles, mumps, rubella and varicella vaccine in healthy children. Arbeter AM; Baker L; Starr SE; Plotkin SA Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864 [TBL] [Abstract][Full Text] [Related]
44. A search for persistent measles, mumps, and rubella vaccine virus in children with human immunodeficiency virus type 1 infection. Frenkel LM; Nielsen K; Garakian A; Cherry JD Arch Pediatr Adolesc Med; 1994 Jan; 148(1):57-60. PubMed ID: 8143011 [TBL] [Abstract][Full Text] [Related]
45. Measles, mumps, and rubella antibodies in vaccinated Baltimore children. King JC; Lichenstein R; Feigelman S; Luna C; Permutt TJ; Patel J Am J Dis Child; 1993 May; 147(5):558-60. PubMed ID: 8488803 [TBL] [Abstract][Full Text] [Related]
46. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. King SM; Saunders EF; Petric M; Gold R Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367 [TBL] [Abstract][Full Text] [Related]
47. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children. Watson BM; Laufer DS; Kuter BJ; Staehle B; White CJ; Starr SE J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041 [TBL] [Abstract][Full Text] [Related]
48. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy. Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861 [TBL] [Abstract][Full Text] [Related]
49. Antibody response following measles-mumps-rubella vaccine under conditions of customary use. Brunell PA; Weigle K; Murphy MD; Shehab Z; Cobb E JAMA; 1983 Sep; 250(11):1409-12. PubMed ID: 6887461 [TBL] [Abstract][Full Text] [Related]
50. A correlation of measles specific antibodies and the number of plasmacytoid dendritic cells is observed after measles vaccination in 9 month old infants. García-León ML; Bonifaz LC; Espinosa-Torres B; Hernández-Pérez B; Cardiel-Marmolejo L; Santos-Preciado JI; Wong-Chew RM Hum Vaccin Immunother; 2015; 11(7):1762-9. PubMed ID: 26075901 [TBL] [Abstract][Full Text] [Related]
51. Measles, mumps and rubella immunisation in children at risk of infection with human immunodeficiency virus. Molyneaux PJ; Mok JY; Burns SM; Yap PL J Infect; 1993 Nov; 27(3):251-3. PubMed ID: 8308316 [TBL] [Abstract][Full Text] [Related]
52. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. King GE; Markowitz LE; Heath J; Redd SC; Coleman S; Bellini WJ; Sievert A JAMA; 1996 Mar; 275(9):704-7. PubMed ID: 8594268 [TBL] [Abstract][Full Text] [Related]
53. Comparative evaluation of two combined measles-mumps-rubella vaccines based on AIK and Edmonston- Zagreb strains of measles virus. Mirchamsy H; Nilforoushan MA; Shafyi A; Razavi J; Ashtiani MP; Youssofi I; Sassani A; Fateh G; Nassiri S Kitasato Arch Exp Med; 1991 Sep; 64(2-3):141-7. PubMed ID: 1811112 [TBL] [Abstract][Full Text] [Related]
54. Evaluation of live trivalent vaccine of measles AIK-C strain, mumps Hoshino strain and rubella Takahashi strain, by virus-specific interferon-gamma production and antibody response. Nakayama T; Urano T; Osano M; Nakagawa M; Maehara N; Sasaki K; Yamamura AM; Makino S Microbiol Immunol; 1990; 34(6):497-508. PubMed ID: 2120551 [TBL] [Abstract][Full Text] [Related]
55. [Immunity to measles, mumps and rubella in children vaccinated with triple viral vaccine]. Pisón Garcés FJ; Galbe Sánchez-Ventura J; Arcauz Eguren P; Aguirre y Dabán C; Mengual Gil J; Larrad Mur L Aten Primaria; 1995 Mar; 15(4):235-7. PubMed ID: 7703334 [TBL] [Abstract][Full Text] [Related]
56. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126 [TBL] [Abstract][Full Text] [Related]
57. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination. Matter L; Germann D; Bally F; Schopfer K Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781 [TBL] [Abstract][Full Text] [Related]
58. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584 [TBL] [Abstract][Full Text] [Related]
59. Interference of immune globulin with measles and rubella immunization. Siber GR; Werner BG; Halsey NA; Reid R; Almeido-Hill J; Garrett SC; Thompson C; Santosham M J Pediatr; 1993 Feb; 122(2):204-11. PubMed ID: 8429432 [TBL] [Abstract][Full Text] [Related]
60. Immunoglobulin GM and KM genes and measles vaccine-induced humoral immunity. Ovsyannikova IG; Larrabee BR; Schaid DJ; Poland GA Vaccine; 2017 Oct; 35(41):5444-5447. PubMed ID: 28274637 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]